Andrew M Skinner
Overview
Explore the profile of Andrew M Skinner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
279
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Redmond S, Cadnum J, Jencson A, Kaple C, Wilson B, Skinner A, et al.
Clin Infect Dis
. 2025 Mar;
PMID: 40036727
Background: There have been several recent reports of Clostridioides difficile infection (CDI) due to isolates with reduced fidaxomicin susceptibility (minimum inhibitory concentration [MIC] ≥ 2 µg/mL). However, the clinical implications...
2.
Johnson S, Skinner A, Lostutter C, Duke T, Posthaus H
PLoS Negl Trop Dis
. 2025 Feb;
19(2):e0012836.
PMID: 39908342
Enteritis necroticans (EN) in humans caused by infection with Clostridium perfringens type C, once thought limited to the highlands of Papua New Guinea has been identified sporadically worldwide. Outbreaks still...
3.
Baghdadi J, Wessel M, Dubberke E, Lydecker A, Claeys K, Alonso C, et al.
Antimicrob Steward Healthc Epidemiol
. 2024 Oct;
4(1):e168.
PMID: 39411667
Background: infection (CDI) may be misdiagnosed if testing is performed in the absence of signs or symptoms of disease. This study sought to support appropriate testing by estimating the impact...
4.
Drwiega E, Johnson S, Danziger L, Skinner A
Infect Control Hosp Epidemiol
. 2024 Oct;
:1-7.
PMID: 39387193
Background: Reducing rehospitalization has been a primary focus of hospitals and payors. Recurrence of infection (CDI) is common and often results in rehospitalization. Factors that influence rehospitalization for CDI are...
5.
Reveles K, Gonzales-Luna A, Golan Y, Alonso C, Guthmueller B, Tan X, et al.
Open Forum Infect Dis
. 2024 Jul;
11(7):ofae341.
PMID: 39006315
Background: Antibiotic use is a major risk factor for recurrent infection (CDI) due to the associated disruption in gut microbiota. Fecal microbiota, live-jslm (REBYOTA®; RBL, previously RBX2660), is the first...
6.
Wieczorkiewicz J, Skinner A, Cheknis A, Petrella L, Stevens V, Wright L, et al.
Antimicrob Agents Chemother
. 2024 Jul;
68(8):e0069824.
PMID: 38953622
In contrast to the epidemiology 10 years earlier at our hospital when the epidemic restriction endonuclease analysis (REA) group strain BI accounted for 72% of isolates recovered from first-episode infection...
7.
Hunt A, Danziger L, Johnson S, Skinner A
Open Forum Infect Dis
. 2024 Apr;
11(4):ofae153.
PMID: 38665169
Vancomycin and fidaxomicin taper regimens were the most common treatment strategies employed but nearly half of patients (40/83) referred to our infection (CDI) clinic did not require further treatment. The...
8.
Feuerstadt P, Crawford C, Tan X, Pokhilko V, Bancke L, Ng S, et al.
J Clin Gastroenterol
. 2023 Nov;
58(8):818-824.
PMID: 38019088
Goals: To assess fecal microbiota, live-jslm (REBYOTA, abbreviated as RBL, formerly RBX2660) efficacy and safety in participants grouped by recurrent Clostridioides difficile infection (rCDI) risk factors and treatment-related variables. Background:...
9.
Skinner A, Tan X, Westman C, Birris T, Drwiega E, Wang M, et al.
Anaerobe
. 2023 Nov;
84:102788.
PMID: 37931679
Among 23 patients with multiply recurrent Clostridioides difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and...
10.
van Prehn J, Skinner A, Krutova M, Guery B
Clin Microbiol Infect
. 2023 Oct;
30(2):261-262.
PMID: 37865336
No abstract available.